This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesTrendsBuy This Stock JUNS vs. VTYX, XBIT, ORMP, CNTX, BMEA, GALT, CLYM, ASMB, MCRB, and CRVOShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Ventyx Biosciences (VTYX), XBiotech (XBIT), Oramed Pharmaceuticals (ORMP), Context Therapeutics (CNTX), Biomea Fusion (BMEA), Galectin Therapeutics (GALT), Climb Bio (CLYM), Assembly Biosciences (ASMB), Seres Therapeutics (MCRB), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry. Jupiter Neurosciences vs. Ventyx Biosciences XBiotech Oramed Pharmaceuticals Context Therapeutics Biomea Fusion Galectin Therapeutics Climb Bio Assembly Biosciences Seres Therapeutics CervoMed Ventyx Biosciences (NASDAQ:VTYX) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do insiders and institutionals hold more shares of VTYX or JUNS? 97.9% of Ventyx Biosciences shares are held by institutional investors. 18.2% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is VTYX or JUNS more profitable? Jupiter Neurosciences' return on equity of 0.00% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -54.94% -50.01% Jupiter Neurosciences N/A N/A N/A Does the MarketBeat Community favor VTYX or JUNS? Ventyx Biosciences received 30 more outperform votes than Jupiter Neurosciences when rated by MarketBeat users. However, 100.00% of users gave Jupiter Neurosciences an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformVentyx BiosciencesOutperform Votes3146.97% Underperform Votes3553.03% Jupiter NeurosciencesOutperform Votes1100.00% Underperform VotesNo Votes Which has stronger valuation and earnings, VTYX or JUNS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$192.96M-$1.98-0.73Jupiter NeurosciencesN/AN/AN/AN/AN/A Do analysts rate VTYX or JUNS? Ventyx Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 589.66%. Given Ventyx Biosciences' higher probable upside, equities research analysts clearly believe Ventyx Biosciences is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the media refer more to VTYX or JUNS? In the previous week, Ventyx Biosciences had 3 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 3 mentions for Ventyx Biosciences and 0 mentions for Jupiter Neurosciences. Ventyx Biosciences' average media sentiment score of 1.26 beat Jupiter Neurosciences' score of 0.94 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Overall Sentiment Ventyx Biosciences Positive Jupiter Neurosciences Positive SummaryVentyx Biosciences beats Jupiter Neurosciences on 7 of the 12 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.18M$6.86B$5.56B$8.03BDividend YieldN/A2.90%5.36%4.23%P/E RatioN/A7.5422.8118.89Price / SalesN/A259.70406.35106.96Price / CashN/A65.8538.1834.62Price / BookN/A6.566.794.34Net IncomeN/A$143.88M$3.23B$248.27M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$0.64+1.2%N/AN/A$21.18MN/A0.005Gap UpVTYXVentyx Biosciences2.5638 of 5 stars$1.24+3.3%$10.00+706.5%-70.1%$88.20MN/A-0.5330Upcoming EarningsNews CoveragePositive NewsXBITXBiotech1.2962 of 5 stars$2.88-1.0%N/A-65.6%$87.81M$4.01M-2.67100Upcoming EarningsNews CoveragePositive NewsORMPOramed Pharmaceuticals0.9121 of 5 stars$2.24-3.9%N/A-1.3%$85.79M$1.34M20.3610Upcoming EarningsAnalyst UpgradePositive NewsGap DownCNTXContext Therapeutics2.265 of 5 stars$0.94+0.0%$6.17+556.0%-53.0%$84.33MN/A-1.037Analyst ForecastAnalyst RevisionNews CoverageBMEABiomea Fusion3.1125 of 5 stars$2.24+2.3%$23.91+967.4%-82.3%$84.16MN/A-0.5650News CoveragePositive NewsGALTGalectin Therapeutics0.8384 of 5 stars$1.32flat$11.00+733.3%-58.4%$83.40MN/A-1.819CLYMClimb BioN/A$1.23-3.1%$10.00+713.0%N/A$82.99MN/A-0.589ASMBAssembly Biosciences3.6571 of 5 stars$10.82+1.1%$33.00+205.0%+7.8%$82.64M$28.52M-1.61100Upcoming EarningsNews CoverageGap UpMCRBSeres Therapeutics3.3872 of 5 stars$9.31-7.6%$80.00+759.3%-58.5%$81.17M$126.33M-40.48330Upcoming EarningsAnalyst DowngradeNews CoverageCRVOCervoMed3.4208 of 5 stars$9.15+5.9%$27.50+200.5%-57.4%$79.63M$7.14M-4.514News CoveragePositive News Related Companies and Tools Related Companies VTYX Competitors XBIT Competitors ORMP Competitors CNTX Competitors BMEA Competitors GALT Competitors CLYM Competitors ASMB Competitors MCRB Competitors CRVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JUNS Stock Free JUNS Stock Alerts